{
    "clinical_study": {
        "@rank": "70630", 
        "acronym": "Diatolepsy", 
        "arm_group": [
            {
                "arm_group_label": "Type A behaviour profile", 
                "arm_group_type": "Other"
            }, 
            {
                "arm_group_label": "Type B behaviour profile", 
                "arm_group_type": "Other"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will include 100 patients with Type 1 and Type 2 diabetes, split into 2 groups of\n      50 patients according to their behaviour type, and their adaptation to different factors of\n      stress encountered in their lives:\n\n        -  the first group will consist of patients with a characteristic Type A behaviour\n           profile, that is to say patients with a \"proactive, impatient\" behaviour pattern\n\n        -  the second group will consist of patients with a characteristic Type B behaviour\n           profile that is to say patients with a \"calm, slow\" behaviour pattern The objective is\n           to know if the different behaviour patterns are associated with distinct biological\n           markers likely to influence the evolution of the diabetes.\n\n      Participation in this study will be approximately 1h30, patients will participate ONCE ONLY:\n\n        1. they will answer simple questions about their disease and then complete 3\n           questionnaires each with 14 items.\n\n        2. they will meet a clinical psychologist for an interview lasting approximately 45\n           minutes recorded on an audio recorder. The consultation will be used to seek links\n           between the psyche and the disease.\n\n        3. they will provide one blood sample of 12 ml (equivalent to a soup spoon) drawn in the\n           morning."
        }, 
        "brief_title": "STUDY IN LEUCOCYTES FROM PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES GENETIC MARKERS OF INFLAMMATION AND OXIDATIVE STRESS (T\u00c9LOM\u00c8RES/ CANDIDATE GENES) ACCORDING TO THE TYPE A OR TYPE B BEHAVIOUR PROFILE", 
        "condition": [
            "Patients With Type 1 or Type 2 Diabetes", 
            "Patients With a Type A or B Behaviour Profile"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Inflammation"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who have provided written informed consent\n\n          -  Patients with type 1 or type 2 diabetes\n\n          -  Patient admitted for a consultation, as out or in-patients to the\n             Endocrinology-Diabetology-Metabolic diseases department of Dijon CHU\n\n          -  Patient > 18 years\n\n          -  Patient with either a characteristic Type A behaviour profile (Bortner > 210), or a\n             characteristic Type B behaviour profile (Bortner<154)\n\n        Exclusion Criteria:\n\n          -  Persons not covered by national health insurance\n\n          -  Adults under guardianship or wards of court or not intellectually independent\n\n          -  Patients without diabetes\n\n          -  Patients with a mixed A/B behaviour profile (154< Bortner score <210)\n\n          -  Pregnant or breast-feeding women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02080741", 
            "org_study_id": "CHAUVET-GELINIER APJ 2013"
        }, 
        "intervention": {
            "arm_group_label": [
                "Type A behaviour profile", 
                "Type B behaviour profile"
            ], 
            "intervention_name": "Blood sample of 12 ml", 
            "intervention_type": "Other"
        }, 
        "lastchanged_date": "March 5, 2014", 
        "location": {
            "contact": {
                "email": "jean-christophe.chauvet-gelinier@chu-dijon.fr", 
                "last_name": "Jean-Christophe CHAUVET-GELINIER", 
                "phone": "3.80.29.37.69", 
                "phone_ext": "+33"
            }, 
            "facility": {
                "address": {
                    "city": "Dijon", 
                    "country": "France", 
                    "zip": "21079"
                }, 
                "name": "CHU de DIJON"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "STUDY IN LEUCOCYTES FROM PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES GENETIC MARKERS OF INFLAMMATION AND OXIDATIVE STRESS (T\u00c9LOM\u00c8RES/ CANDIDATE GENES) ACCORDING TO THE TYPE A OR TYPE B BEHAVIOUR PROFILE", 
        "other_outcome": [
            {
                "measure": "Complications of diabetes (Nephropathy, Retinopathy, Neuropathy, Coronaropathy)", 
                "safety_issue": "No", 
                "time_frame": "Baselines"
            }, 
            {
                "measure": "Scores on psychiatric/psychological scales", 
                "safety_issue": "No", 
                "time_frame": "Baselines"
            }, 
            {
                "measure": "Analysis of the specific psychological interview EMIC", 
                "safety_issue": "No", 
                "time_frame": "Baselines"
            }
        ], 
        "overall_contact": {
            "email": "jean-christophe.chauvet-gelinier@chu-dijon.fr", 
            "last_name": "Jean-Christophe CHAUVET-GELINIER", 
            "phone": "3.80.29.37.69", 
            "phone_ext": "+33"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Telomere length", 
            "safety_issue": "No", 
            "time_frame": "Baselines"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02080741"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Level of expression of candidate genes", 
            "safety_issue": "No", 
            "time_frame": "Baselines"
        }, 
        "source": "Centre Hospitalier Universitaire Dijon", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centre Hospitalier Universitaire Dijon", 
                "agency_class": "Other"
            }
        }, 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}